nach oben

Journal of Radiation Oncology

Erschienen in:

17.11.2018 | Original Research

Relationship among different skin dose definitions in high-dose-rate (HDR) balloon breast brachytherapy

verfasst von: Yongbok Kim, James D. Christensen, Shaakir Hasan, Mark G. Trombetta

Erschienen in: Journal of Radiation Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

To establish the relationship among various skin dosimetric indices and different volumetric definitions of skin in high-dose-rate (HDR) balloon breast brachytherapy.

Methods

Fifty breast cancer patients were treated with HDR balloon brachytherapy. The MammoSite® applicator was used for 40 patients and the Contura® applicator for 10 patients. Skin structure was retrospectively defined by expanding the skin surface internal to the body with a thickness of 1, 2, 3, 4, or 5 mm in one method. In another method, the skin was defined by expanding its external to the body to demonstrate the maximum point dose on the skin surface. For each skin structure defined by six different methods, three dosimetric data points extracted from dose-volume histograms were compared. Dmax was defined as the maximum point dose, and D1cc and D0.1cc were defined as the minimum dose to 1 cm³ and 0.1 cm³ of the most irradiated skin volume, respectively. The relationship among 18 dosimetric parameters was presented in graphs, and linear curve fitting was performed to provide mathematical formulas.

Results

For each skin definition, the Dmax, D1cc, and D0.1cc values show a linear relationship such that Dmax is the largest, D0.1cc is the next, and D1cc is the smallest value. For each dosimetric parameter, there was a linear relationship among the dosimetric indices for 6 different skin definitions. For clinical use, all linear relationships were displayed in graphs and two parameters for linear fitting were provided. Average R² value for curve fitting was 0.978.

Conclusion

The presented relationships can be developed in each individual institution and convert one dosimetric index to another for different skin definitions.

Wobb JL, Shah C, Chen PY, Wallace M, Ye H, Jawad MS, Grills IS (2016) Brachytherapy-based accelerated partial breast irradiation provides equivalent 10-year outcomes to whole breast irradiation: a matched-pair analysis. Am J Clin Oncol 39(5):468–472. https://doi.org/10.1097/COC.0000000000000082 CrossRefPubMed

Vargo JA, Verma V, Kim H, Kalash R, Heron DE, Johnson R, Beriwal S (2014) Extended (5-year) outcomes of accelerated partial breast irradiation using MammoSite balloon brachytherapy: patterns of failure, patient selection, and dosimetric correlates for late toxicity. Int J Radiat Oncol Biol Phys 88(2):285–291. https://doi.org/10.1016/j.ijrobp.2013.05.039 CrossRefPubMed

Cuttino LW, Arthur DW, Vicini F, Todor D, Julian T, Mukhopadhyay N (2014) Long-term results from the Contura multilumen balloon breast brachytherapy catheter phase 4 registry trial. Int J Radiat Oncol Biol Phys 90(5):1025–1029. https://doi.org/10.1016/j.ijrobp.2014.08.341 CrossRefPubMed

Mann JM, Osian AD, Brandmaier A, Yan W, Sung KJ, Siegel B, Fink S, Kaplan B, Fulman M, Wu G, Christos P, Nori D, Ravi A (2016) Excellent long-term breast preservation rate after accelerated partial breast irradiation using a balloon device. Clin Breast Cancer 16(3):217–222. https://doi.org/10.1016/j.clbc.2016.02.010 CrossRefPubMed

Shah C, Khwaja S, Badiyan S, Wilkinson JB, Vicini FA, Beitsch P, Keisch M, Arthur D, Lyden M (2013) Brachytherapy-based partial breast irradiation is associated with low rates of complications and excellent cosmesis. Brachytherapy 12(4):278–284. https://doi.org/10.1016/j.brachy.2013.04.005 CrossRefPubMed

Cuttino LW, Heffernan J, Vera R, Rosu M, Ramakrishnan VR, Arthur DW (2011) Association between maximal skin dose and breast brachytherapy outcome: a proposal for more rigorous dosimetric constraints. Int J Radiat Oncol Biol Phys 81(3):e173–e177. https://doi.org/10.1016/j.ijrobp.2010.12.023 CrossRefPubMed

Lee K, Quillo A, Dillon D, Sowards K, Hatmaker A, Dragun A (2012) Acute toxicity and early cosmetic outcome in patients treated with multilumen balloon brachytherapy with skin spacing </= 7.0 millimeters. J Contemp Brachytherapy 4(1):8–13. https://doi.org/10.5114/jcb.2012.27946 CrossRefPubMedPubMedCentral

Rana Z, Nasr NM, Ji H, Lorio V, Akbari S, Sebastian M, Martin M, Hong RL (2015) Comparative dosimetric findings using accelerated partial breast irradiation across five catheter subtypes. Radiat Oncol 10:160. https://doi.org/10.1186/s13014-015-0468-7 CrossRefPubMedPubMedCentral

Arthur DW, Vicini FA, Todor DA, Julian TB, Cuttino LW, Mukhopadhyay ND (2013) Contura multi-lumen balloon breast brachytherapy catheter: comparative dosimetric findings of a phase 4 trial. Int J Radiat Oncol Biol Phys 86(2):264–269. https://doi.org/10.1016/j.ijrobp.2013.01.005 CrossRefPubMed

10.

Kim Y, Johnson M, Trombetta MG, Parda DS, Miften M (2008) Investigation of interfraction variations of MammoSite balloon applicator in high-dose-rate brachytherapy of partial breast irradiation. Int J Radiat Oncol Biol Phys 71(1):305–313. https://doi.org/10.1016/j.ijrobp.2008.01.024 CrossRefPubMed

11.

Arthur DW, Vicini FA, Todor DA, Julian TB, Lyden MR (2011) Improvements in critical dosimetric endpoints using the Contura multilumen balloon breast brachytherapy catheter to deliver accelerated partial breast irradiation: preliminary dosimetric findings of a phase iv trial. Int J Radiat Oncol Biol Phys 79(1):26–33. https://doi.org/10.1016/j.ijrobp.2009.10.025 CrossRefPubMed

12.

Fu W, Kim JO, Chen AS, Mehta K, Pucci P, Huq MS (2015) Dosimetric experience with 2 commercially available multilumen balloon-based brachytherapy to deliver accelerated partial-breast irradiation. Med Dosim 40(3):195–200. https://doi.org/10.1016/j.meddos.2014.11.005 CrossRefPubMed

13.

Yashar C, Attai D, Butler E, Einck J, Finkelstein S, Han B, Hong R, Komarnicky L, Lyden M, Mantz C, Morcovescu S, Nigh S, Perry K, Pollock J, Reiff J, Scanderbeg D, Snyder M, Kuske R (2016) Strut-based accelerated partial breast irradiation: report of treatment results for 250 consecutive patients at 5 years from a multicenter retrospective study. Brachytherapy 15(6):780–787. https://doi.org/10.1016/j.brachy.2016.07.002 CrossRefPubMed

14.

Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB (2014) A phase ii trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I and Iia breast carcinoma. J Radiat Oncol 3(4):371–378. https://doi.org/10.1007/s13566-014-0153-8 CrossRefPubMedPubMedCentral

15.

NSABP PROTOCOL B-39 RTOG PROTOCOL 0413 (2018) A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. rpc.mdanderson.org/rpc/credentialing/files/B39_Protocol1.pdf. Accessed 05 May 2018

16.

Kim Y, Trombetta MG (2011) Objective method to report planner-independent skin/rib maximal dose in balloon-based high dose rate (HDR) brachytherapy for breast cancer. Med Phys 38(4):2053–2057. https://doi.org/10.1118/1.3568927 CrossRefPubMed

17.

Iftimia I, Cirino ET, Ladd R, Mower HW, McKee AB (2013) Retrospective review of Contura HDR breast cases to improve our standardized procedure. Med Dosim 38(2):133–142. https://doi.org/10.1016/j.meddos.2012.10.001 CrossRefPubMed

18.

Thrower SL, Shaitelman SF, Bloom E, Salehpour M, Gifford K (2016) Comparison of dose distributions with TG-43 and collapsed cone convolution algorithms applied to accelerated partial breast irradiation patient plans. Int J Radiat Oncol Biol Phys 95(5):1520–1526. https://doi.org/10.1016/j.ijrobp.2016.03.033 CrossRefPubMed

19.

Hilts M, Halperin H, Morton D, Batchelar D, Bachand F, Chowdhury R, Crook J (2015) Skin dose in breast brachytherapy: defining a robust metric. Brachytherapy 14(6):970–978. https://doi.org/10.1016/j.brachy.2015.08.002 CrossRefPubMed

20.

Lasota J, Kabacinska R, Makarewicz R (2014) Dose estimation for different skin models in interstitial breast brachytherapy. J Contemp Brachytherapy 6(2):200–207. https://doi.org/10.5114/jcb.2014.43167 CrossRefPubMedPubMedCentral

21.

Gifford KA, Pacha O, Hebert AA, Nelson CL, Kirsner SM, Ballo MT, Bloom ES (2013) A new paradigm for calculating skin dose. Brachytherapy 12(2):114–119. https://doi.org/10.1016/j.brachy.2012.05.005 CrossRefPubMed

22.

Bentzen SM, Christensen JJ, Overgaard J, Overgaard M (1988) Some methodological problems in estimating radiobiological parameters from clinical data. Alpha/beta ratios and electron RBE for cutaneous reactions in patients treated with postmastectomy radiotherapy. Acta Oncol 27(2):105–116CrossRef

23.

Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS (1995) Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22(2):209–234. https://doi.org/10.1118/1.597458 CrossRefPubMed

24.

Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, Mitch MG, Nath R, Williamson JF (2004) Update of AAPM Task Group No. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 31(3):633–674. https://doi.org/10.1118/1.1646040 CrossRefPubMed

25.

Beaulieu L, Carlsson Tedgren A, Carrier JF, Davis SD, Mourtada F, Rivard MJ, Thomson RM, Verhaegen F, Wareing TA, Williamson JF (2012) Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: current status and recommendations for clinical implementation. Med Phys 39(10):6208–6236. https://doi.org/10.1118/1.4747264 CrossRefPubMed

26.

Kassas B, Mourtada F, Horton JL, Lane RG (2004) Contrast effects on dosimetry of a partial breast irradiation system. Med Phys 31(7):1976–1979. https://doi.org/10.1118/1.1763006 CrossRefPubMed

27.

Ye SJ, Brezovich IA, Shen S, Kim S (2004) Dose errors due to inhomogeneities in balloon catheter brachytherapy for breast cancer. Int J Radiat Oncol Biol Phys 60(2):672–677. https://doi.org/10.1016/j.ijrobp.2004.05.039 CrossRefPubMed

28.

Oh S, Scott J, Shin DH, Suh TS, Kim S (2009) Measurements of dose discrepancies due to inhomogeneities and radiographic contrast in balloon catheter brachytherapy. Med Phys 36(9):3945–3954. https://doi.org/10.1118/1.3183497 CrossRefPubMed

Titel: Relationship among different skin dose definitions in high-dose-rate (HDR) balloon breast brachytherapy
verfasst von: Yongbok Kim
James D. Christensen
Shaakir Hasan
Mark G. Trombetta
Publikationsdatum: 17.11.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Radiation Oncology / Ausgabe 4/2018
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-018-0364-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Relationship among different skin dose definitions in high-dose-rate (HDR) balloon breast brachytherapy

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Clinical evidence for dose tolerance of the central nervous system in hypofractionated radiotherapy

Inter-fraction movements of the prostate and pelvic lymph nodes during IGRT

A fiducial-less tracking method for radiation therapy of liver tumors by diaphragm disparity analysis part 2: validation study by using clinical data

Evaluation of effectiveness of palliative radiotherapy for bone metastases: a prospective cohort study

Acute toxicities after volumetric modulated arc therapy for craniospinal irradiation in adults

Experience with hypofractionated stereotactic radiosurgery in a series of patients with skull base tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie